Information Provided By:
Fly News Breaks for December 17, 2019
Dec 17, 2019 | 11:25 EDT
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $100 price target on Biohaven Pharmaceutical following positive efficacy and safety data from the Phase II/III trial of the company's third generation anti-CGRP candidate vazegepant. Van Buren tells investors in a research n ote that the drug from the NOJECTION platform achieved an ultra-rapid 15 minute onset of action due to its intranasal mode of administration and superior solubility, and, like rimegepant, sustained efficacy out to 48 hours and zero liver toxicity was also observed. The analyst says the company now definitively has a second anti-CGRP product via vazegepant which is complementary to oral ODT rimegepant.
News For BHVN From the Last 2 Days
There are no results for your query BHVN